Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults
This paper reviews the current literature and information on the combination drug Complera™ (rilpivirine/emtricitabine/tenofovir disoproxil fumarate) that was approved by the Food and Drug Administration (FDA) in August 2011. PubMed, Cochrane and Embase (2001–2014) were searched for primary and revi...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | article |
| Published: |
2015
|
| Online Access: | http://hdl.handle.net/10725/4480 http://dx.doi.org/10.1016/j.jiph.2015.04.020 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php http://www.sciencedirect.com/science/article/pii/S1876034115000878 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1864513463652450304 |
|---|---|
| author | Kabbara, Wissam K. |
| author2 | Ramadan, Wijdan H. |
| author2_role | author |
| author_facet | Kabbara, Wissam K. Ramadan, Wijdan H. |
| author_role | author |
| dc.creator.none.fl_str_mv | Kabbara, Wissam K. Ramadan, Wijdan H. |
| dc.date.none.fl_str_mv | 2015 2016-10-03T06:28:51Z 2016-10-03T06:28:51Z 2016-10-03 |
| dc.identifier.none.fl_str_mv | 1876-0341 http://hdl.handle.net/10725/4480 http://dx.doi.org/10.1016/j.jiph.2015.04.020 Kabbara, W. K., & Ramadan, W. H. (2015). Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults. Journal of infection and public health, 8(5), 409-417. http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php http://www.sciencedirect.com/science/article/pii/S1876034115000878 |
| dc.language.none.fl_str_mv | en |
| dc.relation.none.fl_str_mv | Journal of Infection and Public Health |
| dc.rights.*.fl_str_mv | info:eu-repo/semantics/openAccess |
| dc.title.none.fl_str_mv | Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults |
| dc.type.none.fl_str_mv | Article info:eu-repo/semantics/publishedVersion info:eu-repo/semantics/article |
| description | This paper reviews the current literature and information on the combination drug Complera™ (rilpivirine/emtricitabine/tenofovir disoproxil fumarate) that was approved by the Food and Drug Administration (FDA) in August 2011. PubMed, Cochrane and Embase (2001–2014) were searched for primary and review articles on rilpivirine, emtricitabine, and tenofovir disoproxil fumarate, individually or in combination. Data from drug manufacturer and product label was also used. Clinical trial reports were selected, extracted and analyzed to include relevant and recent ones. Selected English-language trials were limited to those with human subjects and included both safety and efficacy outcomes. Results from two phase 3 randomized double blind trials (ECHO and THRIVE) showed that rilpivirine is non-inferior to efavirenz in suppressing viral load below 50 copies/mL in anti-retroviral therapy (ART) naïve human immunodeficiency virus (HIV) infected patients. In addition, psychiatric disturbances, rash and increase in lipid levels occurred less frequently with rilpivirine when compared to efavirenz. However, virological failure and drug resistance were higher with rilpivirine in patients with baseline viral load >100,000 copies/mL. Rilpivirine showed cross resistance to efavirenz and etravirine. Efavirenz, on the other hand, did not demonstrate cross resistance to rilpivirine and etravirine, leaving the latter drugs as options for use in case of virological failure with efavirenz. Complera™ remains an acceptable alternative treatment to Atripla™ in ART naïve patients who have a pre-ART plasma HIV RNA <100,000 copies/mL and CD4 count >200 cells/mm3 with non-inferior efficacy and better safety and tolerability. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | LAURepo_bcf6ee21e6b534be094fc834c6f4e622 |
| identifier_str_mv | 1876-0341 Kabbara, W. K., & Ramadan, W. H. (2015). Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults. Journal of infection and public health, 8(5), 409-417. |
| language_invalid_str_mv | en |
| network_acronym_str | LAURepo |
| network_name_str | Lebanese American University repository |
| oai_identifier_str | oai:laur.lau.edu.lb:10725/4480 |
| publishDate | 2015 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| spelling | Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adultsKabbara, Wissam K.Ramadan, Wijdan H.This paper reviews the current literature and information on the combination drug Complera™ (rilpivirine/emtricitabine/tenofovir disoproxil fumarate) that was approved by the Food and Drug Administration (FDA) in August 2011. PubMed, Cochrane and Embase (2001–2014) were searched for primary and review articles on rilpivirine, emtricitabine, and tenofovir disoproxil fumarate, individually or in combination. Data from drug manufacturer and product label was also used. Clinical trial reports were selected, extracted and analyzed to include relevant and recent ones. Selected English-language trials were limited to those with human subjects and included both safety and efficacy outcomes. Results from two phase 3 randomized double blind trials (ECHO and THRIVE) showed that rilpivirine is non-inferior to efavirenz in suppressing viral load below 50 copies/mL in anti-retroviral therapy (ART) naïve human immunodeficiency virus (HIV) infected patients. In addition, psychiatric disturbances, rash and increase in lipid levels occurred less frequently with rilpivirine when compared to efavirenz. However, virological failure and drug resistance were higher with rilpivirine in patients with baseline viral load >100,000 copies/mL. Rilpivirine showed cross resistance to efavirenz and etravirine. Efavirenz, on the other hand, did not demonstrate cross resistance to rilpivirine and etravirine, leaving the latter drugs as options for use in case of virological failure with efavirenz. Complera™ remains an acceptable alternative treatment to Atripla™ in ART naïve patients who have a pre-ART plasma HIV RNA <100,000 copies/mL and CD4 count >200 cells/mm3 with non-inferior efficacy and better safety and tolerability.PublishedN/A2016-10-03T06:28:51Z2016-10-03T06:28:51Z20152016-10-03Articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article1876-0341http://hdl.handle.net/10725/4480http://dx.doi.org/10.1016/j.jiph.2015.04.020Kabbara, W. K., & Ramadan, W. H. (2015). Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults. Journal of infection and public health, 8(5), 409-417.http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.phphttp://www.sciencedirect.com/science/article/pii/S1876034115000878enJournal of Infection and Public Healthinfo:eu-repo/semantics/openAccessoai:laur.lau.edu.lb:10725/44802021-03-19T10:00:50Z |
| spellingShingle | Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults Kabbara, Wissam K. |
| status_str | publishedVersion |
| title | Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults |
| title_full | Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults |
| title_fullStr | Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults |
| title_full_unstemmed | Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults |
| title_short | Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults |
| title_sort | Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults |
| url | http://hdl.handle.net/10725/4480 http://dx.doi.org/10.1016/j.jiph.2015.04.020 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php http://www.sciencedirect.com/science/article/pii/S1876034115000878 |